Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

London’s FTSE 100 was muted on Thursday after its longest gaining streak since 2017, with a slate of disappointing earnings ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...

A trial shows that semaglutide stops fat accumulation and liver fibrosis in a disease associated with metabolic dysfunction ...

Hims & Hers is an increasingly profitable, vertically integrated telehealth platform with major tailwinds, positioning it as ...

Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...

FAT jabs like Ozempic are set to get the seal of approval from the World Health Organisation (WHO). This would back the use ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...